Decision to amend the diphtheria, pertussis and tetanus vaccine (Boostrix) listing
Decision to amend the diphtheria, pertussis and tetanus vaccine (Boostrix) listing
Free whooping cough immunisation for more pregnant women
A free whooping cough vaccine will be available to all pregnant women from 1 January 2013 to help protect their new-born babies from this serious disease.
Proposal to fund sildenafil for the treatment of Raynaud’s phenomenon
Closed: Friday, 21 December 2012.
Proposal to fund capsaicin cream, atenolol oral liquid and bosentan and to amend the listing of erythromycin lactobionate IV
Closed.
PHARMAC lifts restrictions on some cancer treatments
PHARMAC steps up to help meet Government cancer treatment goal.
Recent decisions by PHARMAC will have a positive effect on cancer treatment in New Zealand.
Proposal involving Voluven and Volulyte 6% approved
Proposal involving Voluven and Volulyte 6% approved
Diabetes meters change reaches next milestone
People with diabetes are being reminded about changes to blood glucose testing meters and testing strips.
From 1 December PHARMAC will stop funding meters other than the three meters from the CareSens range.
PHARMAC consulting on clinical advice for medical devices
PHARMAC asking: How do we get the best advice for our medical devices work?
PHARMAC has released a consultation document seeking the views of clinicians. It asks how PHARMAC should make decisions on medical devices, when the agency takes over management of them in 2015.
More convenient HIV treatments funded
PHARMAC is to fund new combination HIV medicines from 1 December. Atripla and Truvada are both combination pills for the treatment of people with HIV. Atripla...
Decision in relation to bosentan (Tracleer)
Decision in relation to bosentan (Tracleer)
Decision in relation to the Sole Supply of Sildenafil (Silagra)
Decision in relation to the Sole Supply of Sildenafil (Silagra)
Approval of proposal to list Atripla and Truvada
Approval of proposal to list Atripla and Truvada
Notification to remove the Special Authority Criteria from various oncology products and pioglitazone
PHARMAC is pleased to announce the approval of a proposal to widen funded access on a number of products from 1 December 2012 by removing the...
Decision on proposal for various Novartis products
PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Limited for Neoral, Aclasta, Zometa and Risedronate Sandoz.
Notification of release of invitation to tender - 2012/13
Notification of release of Invitation to tender, 2012/13
Approval of proposal relating to azithromycin
Approval of proposal relating to azithromycin
Newsletters
Device Advice: Your update on PHARMAC’s Hospital Medical Devices programme.
Hospital News: News about getting the best value for what we spend on hospital pharmaceuticals.
Inpharmation: News about PHARMAC's activities and pharmaceutical-related issues.
Inpharmation in Hospitals: Hospital news about PHARMAC's activities and pharmaceutical-related issues.
Te Whaioranga ePānui: A PHARMAC newsletter for people with an interest in Māori health.
